Filtered By:
Source: The American Journal of Cardiology
Condition: Atrial Fibrillation
This page shows you your search results in order of relevance. This is page number 20.
Order by Relevance | Date
Total 336 results found since Jan 2013.
Comparison of Frequency of Atrial Fibrillation in Blacks versus Whites and the Utilization of Race in a Novel Risk Score
Atrial fibrillation (AF) is the most prevalent sustained arrhythmia in the world, with over 30 million people affected as of 2010.1 The number of patients projected to develop AF will double over the next decade.2 AF is independently associated with an increased risk of stroke,3 heart failure (HF),4 and mortality.5 It is not surprising, thus, that AF assumes a sizeable share of health care expenditure and its magnitude is reaching epidemic proportions.6 Blacks despite having a higher prevalence of traditional risk factors for AF, such as HF, hypertension, and diabetes mellitus, have been shown to have a lower incidence of AF.
Source: The American Journal of Cardiology - August 27, 2020 Category: Cardiology Authors: Gurukripa N. Kowlgi, Sampath Gunda, Santosh K. Padala, Jayanthi N. Koneru, Abhishek J. Deshmukh, Kenneth A. Ellenbogen Source Type: research
Network Meta-analysis Comparing Apixaban versus Rivaroxaban in Morbidly Obese Patients with Atrial Fibrillation
The efficacy and safety of DOACs in morbidly obese patients have been well investigated over the last few years.1-4 Our recent meta-analysis showed that the DOAC group did not increase stroke or systemic embolism (SE) event rate compared to the warfarin group and the DOAC use was significantly associated with a lower major bleeding event rate compared to the warfarin group.5 However, it is still unknown which DOAC is more appropriate than others. Apixaban and rivaroxaban are the two most common DOACs prescribed in the U.S but there is no guidance on which agent should be selected in morbidly obese patients with AF.
Source: The American Journal of Cardiology - September 7, 2020 Category: Cardiology Authors: Kazuhiko Kido, Mikiko Shimizu, Tsuyoshi Shiga, Masayuki Hashiguchi Source Type: research
Comparison in Patients < 75 Years of Age - vs – Those > 75 Years on One-Year-Events with Atrial Fibrillation and Left Atrial Appendage Occluder (From the Prospective Multicenter German LAARGE Registry)
Left atrial appendage closure (LAAC) is an alternative to oral anticoagulation therapy in patients with non-valvular atrial fibrillation for the prevention of embolic stroke and systemic embolism. Although elderly patients (>75 years) have both higher ischemic and bleeding risk as compared to younger patients, they benefit from optimal anticoagulation. The sub-analysis aimed to assess the indications, the safety, efficacy, and 1-year outcomes of interventional LAAC in elderly patients ( ≥ 75 years) compared to younger (
Source: The American Journal of Cardiology - September 13, 2020 Category: Cardiology Authors: Aref El Nasasra, Johannes Brachmann, Thorsten Lewalter, Ibrahim Akin, Horst Sievert, Christoph A. Nienaber, Christian Wei ß, Sven T. Pleger, Hüseyin Ince, Jens Maier, Stephan Achenbach, Holger H. Sigusch, Matthias Hochadel, Steffen Schneider, Jochen Sen Source Type: research
Relation of Interatrial Block to Cognitive Impairment in Patients ≥ 70 Years of Age (From the CAMBIAD Case-Control Study)
The association between atrial fibrillation, stroke, and interatrial block (IAB) (P-wave duration ≥120 ms) is well recognized, particularly in the case of advanced IAB. We aimed to assess the association of IAB with mild cognitive impairment. CAMBIAD (Advanced Characterization of Cognitive Impairment in Elderly with Interatrial Block) was a case-control multicenter study, conducted in subjects aged ≥70 years in sinus rhythm without significant structural heart disease. Diagnosis of mild cognitive impairment was performed by an expert geriatrician, internist, or neurologist in the presence of changes in cognitive functi...
Source: The American Journal of Cardiology - September 14, 2020 Category: Cardiology Authors: Cristian Herrera, Vanesa Bru ña, Pedro Abizanda, Pablo Díez-Villanueva, Francesc Formiga, Rosa Torres, José Carreras, Rocio Ayala, F. Javier Martin-Sánchez, Antoni Bayés-Genis, Roberto Elosua, Antonio Bayés-de-Luna, Manuel Martínez-Sellés, CAMBIAD Source Type: research
Comparison in Patients < 75 Years of Age - Versus – Those > 75 Years on One-year-Events With Atrial Fibrillation and Left Atrial Appendage Occluder (From the Prospective Multicenter German LAARGE Registry)
Left atrial appendage closure (LAAC) is an alternative to oral anticoagulation therapy in patients with non-valvular atrial fibrillation for the prevention of embolic stroke and systemic embolism. Although elderly patients (>75 years) have both higher ischemic and bleeding risk as compared with younger patients, they benefit from optimal anticoagulation. The subanalysis aimed to assess the indications, the safety, efficacy, and 1-year outcomes of interventional LAAC in elderly patients ( ≥ 75 years) compared with younger (
Source: The American Journal of Cardiology - September 13, 2020 Category: Cardiology Authors: Aref El Nasasra, Johannes Brachmann, Thorsten Lewalter, Ibrahim Akin, Horst Sievert, Christoph A. Nienaber, Christian Wei ß, Sven T. Pleger, Hüseyin Ince, Jens Maier, Stephan Achenbach, Holger H. Sigusch, Matthias Hochadel, Steffen Schneider, Jochen Sen Source Type: research
Dose of Direct Oral Anticoagulants and Adverse Outcomes in Asia
One of the main purposes in the treatment of patients with atrial fibrillation (AF) is the prevention of stroke or systemic embolism. In the current clinical practice, direct oral anticoagulants (DOACs) have been approved for thromboembolism prevention in patients with non-valvular atrial fibrillation (NVAF). Each DOAC has specific dose reduction criteria considering age, renal function, body weight, and concomitant medications. A previous report from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II [ORBIT-AF II] showed that a significant minority (almost 1 in 8) of U.S.
Source: The American Journal of Cardiology - October 12, 2020 Category: Cardiology Authors: Junichi Ohno, Yohei Sotomi, Akio Hirata, Yasushi Sakata, Atsushi Hirayama, Yoshiharu Higuchi Source Type: research
Meta-Analysis Comparing the Frequency of Carotid Artery Stenosis in Patients with Atrial Fibrillation and Vice Versa
Atrial fibrillation (AF) and carotid stenosis (CS) can co-exist and this association has been reported to result in a higher risk of stroke than attributed to either condition alone. Here we aimed to summarize the data on the association of CS and AF. MEDLINE and Embase were searched to identify all published studies providing relevant data through 27 February 2020. Random-effects meta-analysis method was used to pool estimates of prevalence. Heterogeneity was assessed by mean I-squared statistic.
Source: The American Journal of Cardiology - October 13, 2020 Category: Cardiology Authors: Jean Jacques Noubiap, Thomas A. Agbaedeng, Joel Noutakdie Tochie, Jan Ren é Nkeck, Aude Laetitia Ndoadoumgue, John L. Fitzgerald, Timothy Kleinig, Gijo Thomas, Melissa E. Middeldorp, Prashanthan Sanders Source Type: research
Safety and Effectiveness of Long-term Anticoagulation for Atrial Fibrillation Among Nonagenarians: A Real-world Analysis
The prevalence of atrial fibrillation (AF) increases with age, reaching 10% among those over 80 years old (1). Long-term anticoagulation (AC) is effective in reducing strokes among patients with AF at increased risk of thromboembolic events (2). The safety and effectiveness of AC among nonagenarians are poorly understood, since these patients were underrepresented in the pivotal trials of AC.1 While age is an independent risk factor for stroke in patients with AF, the net clinical benefit of AC may be mitigated by an increased risk of bleeding (3,4).
Source: The American Journal of Cardiology - November 11, 2020 Category: Cardiology Authors: Ahmed Elkaryoni, Kirolos Barssoum, Amr F. Barakat, Islam Y. Elgendy, Mahmoud Elsayed, Adel Muhanna, Anne Arnason, Islam Shatla, Amir Darki, Alan P. Wimmer Source Type: research
Effect of Adenotonsillectomy on Cardiac function in Children Age 5-13 years with Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) is associated with hypertension, stroke, heart failure, coronary artery disease and atrial fibrillation in adults1-5. Currently, there is conflicting evidence regarding the degree of improvement in cardiovascular outcomes among adults who are treated for OSA6, 7. Several studies have shown that continuous positive airway pressure (CPAP) therapy in adults partially reverses left ventricular (LV) and right ventricular (RV) dysfunction6, lowers blood pressure8, decreases pulmonary artery pressure9 and improves endothelial dysfunction10.
Source: The American Journal of Cardiology - November 18, 2020 Category: Cardiology Authors: Keren Armoni Domany, Guixia Huang, Md Monir Hossain, Christine L Schuler, Virend K. Somers, Stephen R. Daniels, Raouf Amin Source Type: research
Procedural and Short-Term Outcomes of Percutaneous Left Atrial Appendage Closure in Patients with Cancer
Percutaneous left atrial appendage closure (LAAC) with the Watchman device (Boston Scientific) has emerged as an alternative to anticoagulation in patients with atrial fibrillation (AF). Cancer is a common comorbidity in patients with AF (1,2). Also, AF patients with cancer reportedly have a higher bleeding risk with a similar or higher stroke risk than those without cancer (3). Thus, AF patients with cancer unsuitable for anticoagulation can be indicated for LAAC to prevent AF-related thromboembolism (2).
Source: The American Journal of Cardiology - December 3, 2020 Category: Cardiology Authors: Toshiaki Isogai, Anas M. Saad, Abdelrahman Ibrahim Abushouk, Shashank Shekhar, Shunsuke Kuroda, Mohamed M. Gad, Oussama M. Wazni, Amar Krishnaswamy, Samir R. Kapadia Source Type: research
Meta-Analysis of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Bioprosthetic Valves
Valvular heart disease is frequently complicated by atrial fibrillation, which is associated with an increased risk of mortality. In the presence of a surgical or transcatheter bioprosthetic valve, patients with atrial fibrillation are at increased risks of systemic thromboembolism.1 Although direct oral anticoagulants (DOACs) have been shown to be non-inferior or superior to warfarin in preventing stroke or thromboembolism associated with nonvalvular atrial fibrillation, the utilization of DOACs in patients with prior bioprosthetic valves has been limited in randomized clinical trials (RCTs).
Source: The American Journal of Cardiology - December 3, 2020 Category: Cardiology Authors: Babikir Kheiri, Ryle Przybylowicz, Timothy F Simpson, Hani Alhamoud, Mohammed Osman, Khidir Dalouk, Babak Nazer, Charles A. Henrikson, Eric Stecker Source Type: research
Influence of Chronic Obstructive Pulmonary Disease on Atrial Mechanics by Speckle Tracking Echocardiography in Patients with Atrial Fibrillation
Atrial remodelling is a key feature in the development and management of atrial fibrillation (AF). In particular atrial fibrosis and stiffness are related to treatment success and adverse events such as incident stroke.1, 2 AF is a common comorbidity in patients with chronic obstructive pulmonary disease (COPD).3 Although previous research has focused mainly on the characterization of the left atrium (LA), AF affects also the right atrium (RA). In patients with COPD, right-sided pressure overload is common due to secondary pulmonary hypertension which could lead to RA remodelling and dysfunction.
Source: The American Journal of Cardiology - December 21, 2020 Category: Cardiology Authors: Laurien Goedemans, Melissa Leung, Pieter van der Bijl, Rachid Abou, Ngoc Mai Vo, Nina Ajmone Marsan, Victoria Delgado, Jeroen J Bax Source Type: research
Inappropriate Dosing of Direct Oral Anticoagulants in Patients with Atrial Fibrillation
Direct Oral Anticoagulants (DOACs) require dose adjustment based on specific patient characteristics, making them prone to incorrect dosing. The current study aimed to evaluate the prevalence of inappropriate DOAC dosing, its predictors, and corresponding outcomes in a single-center cohort of AF patients. We reviewed all patients with AF treated at Mayo Clinic with a DOAC (Apixaban, Rivaroxaban, or Dabigatran) between 2010 and 2017. Outcomes examined were ischemic stroke /transient ischemic attack (TIA)/embolism and bleeding.
Source: The American Journal of Cardiology - December 28, 2020 Category: Cardiology Authors: Alan Sugrue, David Sanborn, Mustapha Amin, Medhat Farwati, Haarini Sridhar, Azza Ahmed, Ramila Mehta, Konstantinos C. Siontis, Siva K. Mulpuru, Abhishek J. Deshmukh, Bernard J. Gersh, Samuel J Asirvatham, Malini Madhavan Source Type: research
Comparison of Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves
The objectives of this study were to evaluate the ambulatory utilization of DOACs and to compare the effectiveness and safety of DOACs versus warfarin in patients with AF and BHVs. We conducted a retrospective cohort study at a large integrated health care delivery system in California. Patients with BHVs and AF treated with warfarin, dabigatran, rivaroxaban or apixaban between September 12, 2011 and June 18, 2020 were identified.
Source: The American Journal of Cardiology - January 30, 2021 Category: Cardiology Authors: Lewei Duan, Jason N Doctor, John L Adams, John A Romley, Leigh-Anh Nguyen, Jaejin An, Ming-Sum Lee Source Type: research
Blood Coagulation Changes With or Without Direct Oral Anticoagulant Therapy Following Transcatheter Aortic Valve Implantation
Thromboembolic events remain clinically unresolved after transcatheter aortic valve implantation (TAVI).1, 2 The mechanism of thromboembolic events after TAVI is multifactorial. The activation of the coagulation pathway induced by valve implantation may stimulate thrombus formation. 1, 3 However, blood coagulation change following TAVI was not fully investigated. The incidence of preexisting atrial fibrillation in patients with severe aortic valve stenosis is as high as 20% –30%.4 Although the use of direct oral anticoagulant (DOAC) for stroke prevention has increased, DOAC use to reduce thrombosis associated with TAVI r...
Source: The American Journal of Cardiology - February 19, 2021 Category: Cardiology Authors: Taiga Katayama, Naoyuki Yokoyama, Yusuke Watanabe, Shinji Takahashi, Hirofumi Hioki, Kazuo Kawasugi, Ken Kozuma Source Type: research
